

# Differentiation between normal renal tissue and renal cell carcinoma using optical coherence tomography (OCT): a prospective human in-vivo study.

Published: 23-09-2010

Last updated: 06-05-2024

Demonstrate the ability of OCT to distinguish malignant renal tissue from benign (normal) renal tissue by means of attenuation-coefficient.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Pending
<b>Health condition type</b>	Renal and urinary tract neoplasms malignant and unspecified
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON34505

### Source

ToetsingOnline

### Brief title

Differentiating renal tumors using in-vivo OCT

### Condition

- Renal and urinary tract neoplasms malignant and unspecified
- Renal and urinary tract therapeutic procedures

### Synonym

renal cell cancer, renal mass

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Academisch Medisch Centrum

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Diagnostics, Kidney, OCT, Renal Cell Carcinoma

## Outcome measures

### Primary outcome

Primary study outcome is the attenuation-coefficient measured by OCT of the 2 tissue types: normal renal parenchyma and malignant (RCC) tissue.

### Secondary outcome

None

## Study description

### Background summary

Differentiation between benign and malignant (small) renal mass by radiological means is difficult and therefore up to 30% of surgery for renal mass is unnecessary. Optical Coherence Tomography (OCT) is a technique that may contribute to improvement of the accuracy of such renal mass.

OCT is an imaging technique analogous to ultrasound except for the fact that it employs light- instead of soundwaves. OCT measures the effective reflection of light in depth of a tissue sample. When a ray of light penetrates into a tissue sample the intensity of the light decreases due to scattering and absorption of light by different structures in the tissue sample (such as nuclei and organelles).

Our hypothesis is that OCT can differentiate malignant from benign tissue by objectivating the decrease of light intensity per millimeter, since the attenuation of light intensity is hypothetically higher in malignant tissue due to the larger size and amount of nuclei and organelles which results in a higher degree of scattering and absorption of light. This attenuation is objectivated as the attenuation-coefficient (or  $\mu t$ ).

### Study objective

Demonstrate the ability of OCT to distinguish malignant renal tissue from

benign (normal) renal tissue by means of attenuation-coefficient.

## Study design

This study is an observational cohort-study with patients scheduled for surgery for a renal mass suspect for malignancy.

## Study burden and risks

OCT is harmless for human beings since it is light-based with a wavelength of 1300 nm.

Since all measurements take place during surgery there are no extra visits necessary.

The operation time is slightly prolonged (max. 5 minutes with a (partial) nephrectomy usually taking about 2 hours of operation time).

## Contacts

### Public

Academisch Medisch Centrum

Meibergdreef 9  
1105 AZ Amsterdam  
NL

### Scientific

Academisch Medisch Centrum

Meibergdreef 9  
1105 AZ Amsterdam  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

3 - Differentiation between normal renal tissue and renal cell carcinoma using optic ... 13-05-2025

Adults (18-64 years)  
Elderly (65 years and older)

## Inclusion criteria

> 18 yrs  
solid, enhancing renal mass, suspect for malignancy  
scheduled for (open or laparoscopic) nephrectomy or partial nephrectomy  
signed informed consent

## Exclusion criteria

cystic renal mass

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL  
Recruitment status: Pending  
Start date (anticipated): 01-09-2010  
Enrollment: 34  
Type: Anticipated

### Medical products/devices used

Generic name: Optical Coherence Tomography  
Registration: Yes - CE intended use

## Ethics review

Approved WMO

Application type:

First submission

Review commission:

METC Amsterdam UMC

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
CCMO	NL32723.018.10